Biotechnology · San Diego, California, United States
$3.83
-3.16% (-$0.13)2026-08-21
Smart-Money SignalNeutral · 57/100— Insiders are net buyers over 90 days ($15.2M, 3 buys vs 0 sales)
Revenue$0
Net Income-$42.3M
EPS$-1.10
Market Cap$274.1M
Price Performance
Historical data including institutional events
Company Profile
J
Julie Eastland
CEO & Executive Director
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.
It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
